This Article Full Text (PDF) Other Versions of this Article: AAC.01367-07v1 52/4/1493    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Polhemus, M. E. Articles by Heppner, D. G. Search for Related Content PubMed PubMed Citation Articles by Polhemus, M. E. Articles by Heppner, D. G., Jr.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother. doi:10.1128/AAC.01367-07
Copyright (c) 2008, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Malaria Treatment with Atovaquone-Proguanil in Malaria-immune Adults; Implications for Malaria Intervention Trials and for Pre-Exposure Prophylaxis of Malaria

Walter Reed Project, United States Army Medical Research Unit, Kisumu, Kenya; Centre for Clinical Research, Kenya Medical Research Institute, Kisumu, Kenya; GlaxoSmithKline Biologicals, Rixensart, Belgium; Walter Reed Army Institute of Research, Silver Spring, Maryland, USA

^* To whom correspondence should be addressed. Email: mpolhemus{at}wrp-ksm.org.

	Abstract

Eighty adults in holoendemic Kenya received presumptive treatment with atovaquone/proguanil and were followed closely. The time to first Plasmodium falciparum parasitemia was 32 days. This prolonged prophylaxis period has implications for study design when used in malaria intervention trials and cautiously suggests clinical investigation for potential pre-exposure prophylaxis of malaria.